<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00556374</url>
  </required_header>
  <id_info>
    <org_study_id>20050209</org_study_id>
    <secondary_id>ABCSG-18</secondary_id>
    <secondary_id>2005-005275-15</secondary_id>
    <nct_id>NCT00556374</nct_id>
  </id_info>
  <brief_title>Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy</brief_title>
  <official_title>A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects With Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Austrian Breast and Colorectal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether denosumab compared to placebo, will reduce
      the rate of first clinical fracture in women with non-metastatic breast cancer receiving
      (non-steroidal) aromatase inhibitor therapy.

      Subjects who receive open-label denosumab will be followed-up until completion of 36 months
      of treatment. Subject not receiving treatment in the open label phase will be followed for
      approximately 66 months after Primary analysis data cut-off date (PADCD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 18, 2006</start_date>
  <completion_date type="Anticipated">July 8, 2020</completion_date>
  <primary_completion_date type="Actual">March 26, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Clinical Fracture</measure>
    <time_frame>From randomization until the primary analysis cut-off date of 26 March 2014; maximum time on study was 87 months.</time_frame>
    <description>The time to first on-study clinical fracture defined as the number of days from randomization to the date of the x-ray confirming the clinical fracture. A clinical fracture is any clinically evident fracture with associated symptoms and confirmed by x-ray. Participants who died or withdrew without experiencing a clinical fracture were censored at the date of last contact or study termination whichever was earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Bone mineral density was assessed by dual x-ray absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Bone mineral density was assessed by dual x-ray absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites</measure>
    <time_frame>Baseline and Month 36</time_frame>
    <description>Bone mineral density was assessed by dual x-ray absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New Vertebral Fractures</measure>
    <time_frame>36 months</time_frame>
    <description>Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height.
A new vertebral fracture is defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With New or Worsening Vertebral Fractures</measure>
    <time_frame>36 months</time_frame>
    <description>Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height. A new vertebral fracture is defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays. Worsening of pre-existing fractures is defined as an increase in fracture severity of at least 1 grade on the semiquantitative scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>Participants will be followed for disease-free survival (DFS) once every 12 months for 66 months after primary completion date.</time_frame>
    <description>Disease-free survival (DFS) determined by the time from randomization to the first observation of disease recurrence or death from any cause. DFS will be analyzed after long-term follow-up is complete.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Metastases-free Survival</measure>
    <time_frame>Participants will be followed for bone metastasis-free survival once every 12 months for 66 months after primary completion date.</time_frame>
    <description>Bone metastasis-free survival (BMFS) determined by the time from randomization to the first observation of bone metastasis or death from any cause. BMFS will be analyzed after long-term follow-up is complete.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Participants will be followed for overall survival once every 12 months for 66 months after primary completion date.</time_frame>
    <description>Overall survival (OS) determined by the time from randomization to death from any cause. OS will be analyzed after long-term follow-up is complete.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3420</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <arm_group_label>Denosumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-steroidal aromatase inhibitor therapy</intervention_name>
    <description>An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting</description>
    <arm_group_label>Denosumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Double Blinded Phase:

          -  Histologically or cytologically confirmed adenocarcinoma of the breast;

          -  Female subjects with non-metastatic disease who are estrogen receptor (ER) and/or
             progesterone receptor (PR) positive, and who have completed their treatment pathway;

          -  Subjects who are currently on, or will initiate an approved non-steroidal aromatase
             inhibitor therapy (eg, anastrazole) in the adjuvant setting;

          -  Postmenopausal woman, defined as a woman fulfilling any one of the following criteria:

               -  Having undergone a bilateral oophorectomy;

               -  Age ≥ 60 years;

               -  Aged &lt; 60 years meeting the following requirements:

          -  Follicle-stimulating hormone (FSH) and estradiol in the postmenopausal range;

          -  A negative pregnancy test within 7 days prior to randomization. Subjects who have
             undergone a hysterectomy do not require a pregnancy test.

          -  More criteria may apply.

        Exclusion Criteria for Double Blinded Phase:

          -  Aromatase inhibitor therapy for more than 24 months;

          -  Prior or concurrent treatment with Selective Estrogen Receptor Modulators (eg,
             tamoxifen);

          -  Evidence of metastatic disease;

          -  Current or prior intravenous (IV) bisphosphonate administration;

          -  Oral bisphosphonate treatment greater than or equal to 3 years continuously OR greater
             than 3 months but less than 3 years unless there was a washout period of at least 1
             year prior to randomization OR any use during the 3-month period prior to
             randomization;

          -  Prior administration of denosumab;

          -  Known liver or renal deficiency;

          -  Recurrence of the primary malignancy (e.g., during the allowed interval of
             pretreatment with aromatase inhibitor);

          -  Diagnosis of any second non-breast malignancy within the last 5 years, except for
             adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma
             of the cervix uteri;

          -  Any kind of disorder that compromises the ability to give written informed consent
             and/or comply with study procedures.

        Inclusion Criteria to Receive Open-label Phase Denosumab:

          -  Obtain signed and dated written informed consent prior to performing any
             study-specific procedure;

          -  Subjects currently taking an approved non-steroidal AIT (eg, anastrazole) or who have
             completed or discontinued AIT within 12 months prior to participation in the OLP;

          -  Randomized to placebo arm during the double-blind phase (as determined by unblinding
             procedures);

        Exclusion Criteria to Receive Open-label Phase Denosumab:

          -  Current or prior IV bisphosphonate administration;

          -  Subjects meeting the following criteria for oral bisphosphonate treatment:

               -  Greater than or equal to 3 years continuously,

               -  Greater than 3 months but less than 3 years unless subject has had a washout
                  period of at least 1 year prior to participation in the OLP,

               -  Any use during the 3-month period prior to participation in the OLP;

          -  Prior or concurrent treatment with SERMs (eg, tamoxifen);

          -  Subjects who ended treatment with investigational product (IP) prematurely in the
             double-blind phase; Treatment with commercial denosumab (Prolia or Xgeva) prior to
             participation in the OLP.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baden</city>
        <zip>2500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Braunau</city>
        <zip>5280</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dornbirn</city>
        <zip>6850</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Feldkirch</city>
        <zip>6807</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gmunden</city>
        <zip>4810</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Güssing</city>
        <zip>7540</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hall in Tirol</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9026</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krems</city>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kufstein</city>
        <zip>6330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leoben</city>
        <zip>8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lienz</city>
        <zip>9900</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oberpullendorf</city>
        <zip>7350</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ried</city>
        <zip>4910</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rottenmann</city>
        <zip>8786</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schärding</city>
        <zip>4780</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Poelten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Veit an der Glan</city>
        <zip>9300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Poelten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villach</city>
        <zip>9504</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voecklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Weiz</city>
        <zip>8160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wiener Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1050</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1180</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wolfsberg</city>
        <zip>9400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gävle</city>
        <zip>801 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.</citation>
    <PMID>26040499</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2007</study_first_submitted>
  <study_first_submitted_qc>November 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2007</study_first_posted>
  <results_first_submitted>October 6, 2015</results_first_submitted>
  <results_first_submitted_qc>October 6, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2015</results_first_posted>
  <disposition_first_submitted>September 29, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 29, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 7, 2015</disposition_first_posted>
  <last_update_submitted>November 24, 2017</last_update_submitted>
  <last_update_submitted_qc>November 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>confirmed adenocarcinoma</keyword>
  <keyword>non-metastatic breast cancer</keyword>
  <keyword>estrogen receptor positive</keyword>
  <keyword>progesterone receptor positive</keyword>
  <keyword>non-steroidal aromatase</keyword>
  <keyword>aromatase inhibitor therapy</keyword>
  <keyword>postmenopausal woman</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was enrolled on 18 December 2006 and the last patient was enrolled on 22 July 2013. 5 patients randomized withdrew full consent and are not included in any analyses. Results data are reported as of 06 October 2014 (the date of last end of treatment visit).</recruitment_details>
      <pre_assignment_details>Randomization was stratified by type of hospital (major academic centers or other centers), prior aromatase inhibitor usage (Yes/No) and total lumbar spine bone mineral density (BMD) score at baseline (T-score &lt; -1.0 or ≥ -1.0).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy (AIT).</description>
        </group>
        <group group_id="P2">
          <title>Denosumab</title>
          <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1709"/>
                <participants group_id="P2" count="1711"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1699"/>
                <participants group_id="P2" count="1700"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1462">Indicates participants continuing study</participants>
                <participants group_id="P2" count="1491">Indicates participants continuing study</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="247"/>
                <participants group_id="P2" count="220"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="172"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
        </group>
        <group group_id="B2">
          <title>Denosumab</title>
          <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1709"/>
            <count group_id="B2" value="1711"/>
            <count group_id="B3" value="3420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.6" spread="8.0"/>
                    <measurement group_id="B2" value="64.0" spread="7.9"/>
                    <measurement group_id="B3" value="64.3" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1709"/>
                    <measurement group_id="B2" value="1711"/>
                    <measurement group_id="B3" value="3420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White/Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1700"/>
                    <measurement group_id="B2" value="1702"/>
                    <measurement group_id="B3" value="3402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/Afro-Caribbean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Type of Hospital</title>
          <units>particpants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Major Academic Center</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="632"/>
                    <measurement group_id="B2" value="633"/>
                    <measurement group_id="B3" value="1265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Center</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1077"/>
                    <measurement group_id="B2" value="1078"/>
                    <measurement group_id="B3" value="2155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Prior Aromatase inhibitor Use</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="269"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1440"/>
                    <measurement group_id="B2" value="1441"/>
                    <measurement group_id="B3" value="2881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratification Factor: Total Lumbar Spine Bone Mineral Density T-score</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>T-score &lt; -1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="775"/>
                    <measurement group_id="B2" value="773"/>
                    <measurement group_id="B3" value="1548"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-score ≥ -1.0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="934"/>
                    <measurement group_id="B2" value="938"/>
                    <measurement group_id="B3" value="1872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Clinical Fracture</title>
        <description>The time to first on-study clinical fracture defined as the number of days from randomization to the date of the x-ray confirming the clinical fracture. A clinical fracture is any clinically evident fracture with associated symptoms and confirmed by x-ray. Participants who died or withdrew without experiencing a clinical fracture were censored at the date of last contact or study termination whichever was earlier.</description>
        <time_frame>From randomization until the primary analysis cut-off date of 26 March 2014; maximum time on study was 87 months.</time_frame>
        <population>Full analysis set (all randomized participants)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab</title>
            <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Clinical Fracture</title>
          <description>The time to first on-study clinical fracture defined as the number of days from randomization to the date of the x-ray confirming the clinical fracture. A clinical fracture is any clinically evident fracture with associated symptoms and confirmed by x-ray. Participants who died or withdrew without experiencing a clinical fracture were censored at the date of last contact or study termination whichever was earlier.</description>
          <population>Full analysis set (all randomized participants)</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1709"/>
                <count group_id="O2" value="1711"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not reached due to the low number of events</measurement>
                    <measurement group_id="O2" value="NA">Not reached due to the low number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The efficacy clinical hypothesis is that denosumab, when administered subcutaneously at a dose of 60 mg every 6 months, will be considered efficacious in patients with non-metastatic breast cancer receiving AIT if the rate of first clinical fracture in denosumab-treated patients is lower than that in placebo-treated patients. It is anticipated that denosumab will reduce the rate by 30% compared with placebo (ie, the true hazard ratio of denosumab compared with placebo is 0.70).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cox Proportional Hazard Model</method>
            <method_desc>Stratification factors are hospital type, prior use of aromatase inhibitor, and baseline lumbar spine BMD.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.504</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
            <estimate_desc>From the Cox proportional hazard model with treatment as the independent variable and stratified by randomization strata. A hazard ratio &lt; 1.0 indicates a lower average event rate and a longer fracture-free time for denosumab relative to placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites</title>
        <description>Bone mineral density was assessed by dual x-ray absorptiometry.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>BMD analysis set - total lumbar spine at Month 36 (participants with evaluable BMD values at Baseline and Month 36 for total lumbar spine)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab</title>
            <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites</title>
          <description>Bone mineral density was assessed by dual x-ray absorptiometry.</description>
          <population>BMD analysis set - total lumbar spine at Month 36 (participants with evaluable BMD values at Baseline and Month 36 for total lumbar spine)</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" lower_limit="-3.44" upper_limit="-2.07"/>
                    <measurement group_id="O2" value="7.27" lower_limit="6.56" upper_limit="7.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The Hochberg procedure was used to control for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment group as the independent variable and adjusted for baseline value and the randomization stratification factors.</method_desc>
            <param_type>Difference from Placebo</param_type>
            <param_value>10.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.04</ci_lower_limit>
            <ci_upper_limit>11.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites</title>
        <description>Bone mineral density was assessed by dual x-ray absorptiometry.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>BMD analysis set - total hip at Month 36 (participants with evaluable BMD values at Baseline and Month 36 for total hip)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab</title>
            <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites</title>
          <description>Bone mineral density was assessed by dual x-ray absorptiometry.</description>
          <population>BMD analysis set - total hip at Month 36 (participants with evaluable BMD values at Baseline and Month 36 for total hip)</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.32" lower_limit="-4.06" upper_limit="-2.58"/>
                    <measurement group_id="O2" value="4.60" lower_limit="3.85" upper_limit="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The Hochberg procedure was used to control for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment group as the independent variable and adjusted for baseline value and the randomization stratification factors.</method_desc>
            <param_type>Difference from Placebo</param_type>
            <param_value>7.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.87</ci_lower_limit>
            <ci_upper_limit>8.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites</title>
        <description>Bone mineral density was assessed by dual x-ray absorptiometry.</description>
        <time_frame>Baseline and Month 36</time_frame>
        <population>BMD analysis set - femoral neck at Month 36 (participants with evaluable BMD values at Baseline and Month 36 for femoral neck)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab</title>
            <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites</title>
          <description>Bone mineral density was assessed by dual x-ray absorptiometry.</description>
          <population>BMD analysis set - femoral neck at Month 36 (participants with evaluable BMD values at Baseline and Month 36 for femoral neck)</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="238"/>
                <count group_id="O2" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.10" lower_limit="-3.72" upper_limit="-2.48"/>
                    <measurement group_id="O2" value="3.41" lower_limit="2.78" upper_limit="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>The Hochberg procedure was used to control for multiplicity.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Model includes treatment group as the independent variable and adjusted for baseline value and the randomization stratification factors.</method_desc>
            <param_type>Difference from Placebo</param_type>
            <param_value>6.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.62</ci_lower_limit>
            <ci_upper_limit>7.39</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New Vertebral Fractures</title>
        <description>Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height.
A new vertebral fracture is defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays.</description>
        <time_frame>36 months</time_frame>
        <population>Vertebral Fracture Analysis Set with a Baseline and at least one post-baseline vertebral x-ray prior to or at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab</title>
            <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New Vertebral Fractures</title>
          <description>Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height.
A new vertebral fracture is defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays.</description>
          <population>Vertebral Fracture Analysis Set with a Baseline and at least one post-baseline vertebral x-ray prior to or at Month 36.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="809"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0088</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model includes treatment groups as the independent variable and stratified by the randomization stratification factors.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.85</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor denosumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With New or Worsening Vertebral Fractures</title>
        <description>Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height. A new vertebral fracture is defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays. Worsening of pre-existing fractures is defined as an increase in fracture severity of at least 1 grade on the semiquantitative scale.</description>
        <time_frame>36 months</time_frame>
        <population>Vertebral Fracture Analysis Set with a Baseline and at least one post-baseline vertebral x-ray prior to or at Month 36.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
          <group group_id="O2">
            <title>Denosumab</title>
            <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With New or Worsening Vertebral Fractures</title>
          <description>Assessment of vertebral fractures was performed by an expert radiologist at the central imaging center using a semiquantitative grading scale: Grade 1, 20% to 25% reduction in vertebral height (anterior, middle, or posterior); Grade 2, 25% to 40% reduction in height; Grade 3, greater than 40% reduction in height. A new vertebral fracture is defined as a fracture in a previously undeformed vertebrae including new compression fractures, defined as those compression fractures having a decrease in total anterior or posterior height of at least 25% from baseline. New vertebral fractures includes morphometric vertebral fractures identified from on study x-rays and clinical vertebral fractures confirmed by x-rays. Worsening of pre-existing fractures is defined as an increase in fracture severity of at least 1 grade on the semiquantitative scale.</description>
          <population>Vertebral Fracture Analysis Set with a Baseline and at least one post-baseline vertebral x-ray prior to or at Month 36.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="809"/>
                <count group_id="O2" value="835"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0070</p_value>
            <method>Regression, Logistic</method>
            <method_desc>Logistic regression model includes treatment groups as the independent variable and stratified by the randomization stratification factors.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.84</ci_upper_limit>
            <estimate_desc>Values &lt; 1 for odds ratio favor denosumab.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival</title>
        <description>Disease-free survival (DFS) determined by the time from randomization to the first observation of disease recurrence or death from any cause. DFS will be analyzed after long-term follow-up is complete.</description>
        <time_frame>Participants will be followed for disease-free survival (DFS) once every 12 months for 66 months after primary completion date.</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Metastases-free Survival</title>
        <description>Bone metastasis-free survival (BMFS) determined by the time from randomization to the first observation of bone metastasis or death from any cause. BMFS will be analyzed after long-term follow-up is complete.</description>
        <time_frame>Participants will be followed for bone metastasis-free survival once every 12 months for 66 months after primary completion date.</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall survival (OS) determined by the time from randomization to death from any cause. OS will be analyzed after long-term follow-up is complete.</description>
        <time_frame>Participants will be followed for overall survival once every 12 months for 66 months after primary completion date.</time_frame>
        <posting_date>10/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of study drug until 30 days after the last dose; 0.1 - 7.5 years with median of 3.0 years in Placebo arm, and 0.1 - 7.1 years with median of 3.0 years in Denosumab arm</time_frame>
      <desc>Nine participants in the placebo arm received denosumab in error and are counted in this arm for safety analyses.
Other Adverse Events summarizes the non-serious occurrences of adverse events that exceed the indicated frequency threshold.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Q6M</title>
          <description>Participants received placebo subcutaneous injection once every 6 months (Q6M). All participants continued to receive an approved non-steroidal aromatase inhibitor therapy.</description>
        </group>
        <group group_id="E2">
          <title>Denosumab 60mg Q6M</title>
          <description>Participants received 60 mg denosumab subcutaneous injection once every 6 months. All participants continued to receive an approved non-steroidal aromatase inhibitor therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="515" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="521" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental hip dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gene mutation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ear canal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharochalasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cataract cortical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Exfoliation glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vitreous opacities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Colon dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastric antral vascular ectasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Large intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Oesophageal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Painful defaecation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Peritoneal necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Device connection issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Fat necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Eye infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Incision site abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Anastomotic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bursa injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Haemodilution</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Post procedural inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Postoperative hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Postoperative thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Procedural intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Radiation alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Radiation skin injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Splenic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Suture rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Traumatic arthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vascular bypass dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Blood pressure abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Colonoscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Mammogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pulmonary arterial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Smear cervix abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Insulin resistance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired claw toe</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bone cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ligament disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Benign lymph node neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Contralateral breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Inflammatory myofibroblastic tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intraductal papilloma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lip and/or oral cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lobular breast carcinoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Metastases to skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Oral fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ovarian fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Salivary gland adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Schwannoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma urethra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Uterine leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Amnestic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Chronic inflammatory demyelinating polyradiculoneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Drop attacks</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Facial neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Guillain-Barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Medication overuse headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Meralgia paraesthetica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Monoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Morton's neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Motor neurone disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Small fibre neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Burnout syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Psychosomatic disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Urethral disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Urge incontinence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Adnexa uteri cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Adnexa uteri mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast calcifications</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast disorder</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Uterine adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cheyne-Stokes respiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diaphragmatic paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pharyngeal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Sinus polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vocal cord polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired epidermolysis bullosa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Keloid scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lichen sclerosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Breast reconstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hysterosalpingo-oophorectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intraocular lens implant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Oophorectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Subclavian steal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="838" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="882" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="446" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="441" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="139" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="234" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="270" subjects_at_risk="1709"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1690"/>
                <counts group_id="E2" subjects_affected="111" subjects_at_risk="1709"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

